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ABSTRACT
Background Remote ischaemic preconditioning (RIPC) is 
the exposure of body parts to brief periods of circulatory 
occlusion and reperfusion. Recent studies have also shown 
that RIPC can improve exercise performance in healthy 
individuals.
Objective This study aimed to assess the effect of RIPC 
on walking in people with multiple sclerosis (MS).
Methods This was a double- blind randomised controlled 
clinical trial. We used three cycles of RIPC delivered by 
occluding the upper arm with a blood pressure (BP) cuff 
inlated to a pressure of 30 mm Hg above the systolic BP. 
In patients in the sham intervention group, the BP cuff was 
inlated only to 30 mm Hg below diastolic BP. Outcome 
measures included the Six- Minute Walk Test (6MWT), gait 
speed, the Borg rate of perceived exertion (RPE) scale, the 
tolerability of the RIPC using a Numerical Rating Scale for 
discomfort from 0 to 10, and adverse events. We identiied 
responders meeting the minimal clinically important 
difference (MCID) established in the literature in each 
group.
Results Seventy- ive participants completed the study 
(RIPC: 38 and Sham: 37). The distance walked during the 
6MWT improved by 1.9% in the sham group and 5.7% 
in the RIPC group (p=0.012). The number of responders 
meeting MCID criteria in the RIPC group was signiicantly 
greater compared with the sham intervention group. No 
serious adverse events occurred.
Conclusion Single cycle of RIPC resulted in immediate 
improvement in walking distances during 6MWT in people 
with MS.
Trial registration numbers NCT03153553
INTRODUCTION
Regular physical activity improves phys-
ical fitness, fatigue, quality of life and gait 
and also reduces the rate of progression of 
disability in individuals with multiple sclerosis 
(MS).1 However, individuals with MS are less 
physically active than the general population. 
Around 78% of people with MS do not partic-
ipate in any regular physical activity.2 People 
with MS often experience problems with 
gait that limit their participation in physical 
activity. Problems with gait is a concern for 
85% of people with MS.3 Loss of ambulation 
in people with MS is due to multiple factors 
such as muscle weakness, spasticity, ataxia 
and loss of proprioception. Ongoing disease 
progression and deconditioning facilitates a 
self- fulfilling cycle of progressive inactivity. 
People with MS who are unable to walk are at 
risk of developing adverse health conditions 
associated with sedentary lifestyle.
Remote ischaemic preconditioning 
(RIPC) is the exposure of the body to brief 
periods of circulatory occlusion and reper-
fusion to protect organs against ischaemic 
injury.4 5 Although the precise mechanisms 
of ischaemic conditioning are unknown, 
RIPC is thought to induce changes in gene 
expression and cellular function, including 
mitochondrial adaptation to metabolic 
stress and leucocyte activation.5 RIPC may 
improve metabolic efficiency by reducing 
cellular ATP and glycogen depletion and 
decreasing lactate production.6–8 RIPC may 
also improve skeletal muscle blood flow by 
inducing vasodilation through increases in 
nitric oxide production and the number of 
endothelial progenitor cells.9 Recent studies 
have shown that RIPC can also improve 
levels of exercise capacity and performance 
in athletes and healthy volunteers.5 10–12 The 
aim of this study was to evaluate the efficacy 
of RIPC to enhance gait in people with MS.
MATERIALS AND METHODS
Trial design
This study was a double- blind randomised 
controlled trial; the patient and the assessor 
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Figure 1 Study protocol.
were blinded to the intervention. This trial was registered 
with  ClinicalTrials. gov.
Participants
Potential patients were identified by consultant neurol-
ogists and MS specialist nurses of a regional MS clinic 
at Royal Hallamshire Hospital, Sheffield, UK, from May 
2017 to August 2019.
A patient information sheet was given to all potential 
participants deemed suitable for the trial by the treating 
team. Participants were given up to 2 weeks to consider 
their participation in the trial, and those wishing to partic-
ipate were consented and screened for inclusion and 
exclusion criteria. Inclusion criteria comprised (1) diag-
nosis of MS as per 2017 revisions of McDonald’s criteria,13 
(2) age 18 or older, (3) sufficient cognitive ability to give 
informed consent, (4) ability to walk for 6 min and (5) 
resting systolic BP of less than 170 mm Hg.
Patients with one or more of the following were 
excluded: (1) cognitive difficulties in giving consent and 
understanding the questionnaire, (2) inability to walk for 
6 min, (3) other neurological conditions that can affect 
gait like stroke and Parkinson’s disease, (4) systemic 
illness affecting gait and exercise tolerance and (5) 
resting systolic BP of 170 mm Hg or more.
Interventions
Those eligible to participate were randomised into either 
the intervention group (RIPC) or the control group using 
a random number table. The researcher performing the 
assessments and patients remained blind to group assign-
ment. The study protocol is shown in figure 1. Partici-
pants rested in sitting position for 10 min. The resting 
blood pressure (BP) and heart rate were taken using 
an automatic BP monitor (Dinamap, GE). Participants 
were then asked to take part in the Six- Minute Walk Test 
(6MWT). They were asked to walk on a walkway of 14 m 
length back and forward for 6 min at a self- determined 
steady pace. Fluorescent cones were placed on both sides 
of the walkway to indicate where participants should turn. 
The total distance walked during this time was measured. 
Following this, BP and heart rate were measured. The 
patient was asked to grade the level of exertion using the 
Borg rate of perceived exertion (RPE) scale.14 BP and 
heart rate were also measured again after the patient 
rested for 10 min.
The cuff of a manual BP apparatus was tied around the 
upper arm of the RIPC group and was inflated to the pres-
sure 30 mm Hg above the resting systolic BP. The infla-
tion was maintained for 5 min followed by cuff deflation 
lasting 5 min. The cycle was repeated three times.11
The sham intervention was delivered with the manual 
BP tied to the upper arm. The cuff was inflated 30 mm 
Hg below the diastolic BP for 5 min followed by deflation 
for 5 min. The cycle was repeated three times. Partici-
pants were then asked to walk for 6 min on the same 14 
m walkway. Immediately after the 6 min walk, the partici-
pants were asked to rate their level of exertion using the 
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Figure 2 Consort low diagram. 6MWT1, Six- Minute Walk Test 1; RIPC, remote ischaemic preconditioning.
Borg RPE scale, and BP and heart rate measurements 
were taken in the sitting position. Patients were asked if 
they experienced any discomfort using the Numerical 
Rating Scale (NRS) from 0 to 10. Any adverse events were 
also recorded. We particularly looked for redness of skin 
under the cuff, pain, discomfort or any sensory symptoms 
of the limb to which RIPC was applied. Following a 10- min 
rest period, BP and heart rate were measured again.
Outcomes
The primary outcome was percentage improvement in 
6MWT. The 6MWT is a test of endurance.15 The abso-
lute distance change was calculated using the formula 
postintervention distance–preintervention distance. 
The percentage improvement was calculated using the 
formula (postintervention distance–preintervention 
distance/preintervention distance)×100. The 6MWT has 
good reliability and is a strong indicator of exercise toler-
ance in patients with MS.16 17
Predefined secondary outcomes were gait speed, the 
Borg RPE scale, the tolerability of the RIPC and the 
number of people with MS who responded to RIPC. Gait 
speed was calculated using the formula distance walk 
from 6MWT (m)/time walk (s). Exertion during 6MWT 
was assessed before and after intervention using the Borg 
RPE scale, a valid and reliable tool for measuring the 
perceived exertion in people with MS.14 The change in 
exertion was calculated using the formula postinterven-
tion Borg scale–preintervention Borg scale. The tolera-
bility of the intervention was examined using an NRS for 
discomfort due to intervention from 0 to 10 (0 meaning 
no discomfort and 10 meaning the worst discomfort 
possible). All adverse events experienced during the trial 
were recorded. We used the minimal clinically important 
difference (MCID) established in the literature for 
defining response. There are three MCIDs reported in 
the literature for 6MWT for people with MS. They are 
a relative improvement of 7% in 6MWT distance, abso-
lute distance improvement of 9.1 m from patient perspec-
tive and 21.6 m therapist perspective in 6MWT.18 19 The 
number of participants who had achieved the MCID in 
each of these three was calculated.
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Table 1 Clinical characteristics of sham and RIPC groups
Sham intervention 
(n=37)
RIPC intervention 
(n=38)
Age (years), 
mean±SD
44.0±12.5 47.6±11.3
Sex     
  Female, n (%) 27 (73) 17 (44.7)
  Male, n (%) 10 (27) 21 (55.3)
Type of MS     
  Relapsing 
remitting, n (%)
34 (91.9) 27 (71.1)
  Secondary 
progressive, n (%)
1 (2.7) 7 (18.4)
  Primary 
progressive, n ()
2 (5.4) 4 (10.5)
Time since diagnosis 
(months)
137.1±129.6 120.3±128.1
EDSS score, median 
(IQR)
3.5 (2–6) 5 (3.4–6.0)
EDSS score, n (%)     
  0 0 1 (2.6)
  −1.0 3 (8.1) 0
  −1.5 1 (2.7) 2 (5.3)
  −2.0 10 (27%) 2 (5.3%)
  −2.5 1 (2.7) 0
  −3.0 0 4 (10.5)
  −3.5 4 (10.8) 3 (7.9)
  −4.0 1 (2.7%) 2 (5.3)
  −4.5 4 (10.8) 3 (7.9)
  −5.0 2 (5.4) 3 (7.9)
  −5.5 1 (2.7) 2 (5.3)
  −6.0 8 (21.6) 12 (31.6)
  −6.5 2 (5.4) 3 (7.9)
  −7.0 0 1 (2.6)
EDSS, Extended Disability Status Scale; MS, multiple sclerosis; 
N, number of patients; RIPC, remote ischaemic preconditioning.
Table 2 Within- group comparisons before and after 
intervention
Intervention Preintervention Postintervention P value
Absolute 
distance 
walked 
during 
6MWT 
(m), 
mean±SD
Sham 318.2±124.3 324.8±129.4 0.026*
RIPC 288.3±127.7 301.8±123.8 <0.001*
Speed of 
walking 
(m/s), 
mean±SD
Sham 0.88±0.34 0.90±0.36 0.041*
RIPC 0.80±0.35 0.84±0.34 <0.001*
Borg RPE 
scale, 
median 
(IQR)
Sham 11.0 (8.5–13.0) 11.0 (8.5–13.0) 0.184†
RIPC 11.5 (7.8–14.0) 11 (7.0–13.3) 0.143†
*Paired t- test.
†Wilcoxon signed- rank test.
6MWT, Six- Minute Walk Test; RIPC, remote ischaemic preconditioning; RPE, 
rate of perceived exertion.
The literature review showed a mean MCID for the 
6MWT of 7% change.18 Our preliminary data from 22 
patients showed that a sample size of 34 in each group 
would provide 80% power to detect an improvement of 
7% after RIPC with a 0.05 two- sided significance level.
Statistical analysis
Continuous variables were reported using mean±SD 
for normally distributed data or median with IQRs 25 
and 75 for non- normally distributed data (according to 
Kolmogorov- Smirnov and Shapiro- Wilk tests). Categor-
ical variables were presented as number (percentage). 
Paired Student t- tests were used to examine any differ-
ence between the distances walked during 6MWT before 
and after the intervention within each group. Wilcoxon 
signed- rank tests were used to determine if there was 
any significant difference between the Borg’s RPE scale 
before and after intervention within each group. To 
compare quantitative data between two groups, indepen-
dent t- test was used for normally distributed data, and 
Mann- Whitney U- test was employed to analyse for non- 
normally distributed data. Pearson χ2 test was used to 
compare the numbers of responders between groups. All 
statistical analyses were performed using SSPS Statistics 
V.18.0. A p value of <0.05 was considered to be statistically 
significant.
Patient and public involvement (PPI)
There were no funds or time allocated for PPI, so we were 
unable to involve patients. Patients were not invited to 
contribute to the writing or editing of this document for 
readability or accuracy.
RESULTS
We approached 237 patients, of whom 77 consented to 
take part in the study and 75 completed the study. Of the 
160 participants who chose not to participate, 13 did not 
meet the inclusion criteria; 102 did not give any reason; 
33 reported time constraints; and 12 reported that they 
were not interested in this trial. The consort diagram of 
the study is shown on figure 2. Two of the recruited partic-
ipants were excluded from analysis (one in the RIPC 
group due to systolic BP of >170 mm Hg and one in the 
sham group due to incomplete data collection).
Baseline characteristics of both sham and RIPC groups 
are shown in table 1.
Within- group comparisons before and after interven-
tion in the sham and RIPC groups are shown in table 2.
The walking distance improved by 1.9% in the sham 
group and by 5.7% in the RIPC group. Between- group 
comparisons are shown in table 3.
There was a statistically significant improvement in 
the percentage change of distance walked during 6MWT 
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Table 3 Comparison between sham and RIPC intervention groups
Sham intervention (n=37) RIPC intervention (n=38) P value
Distance walked during 6MWT before intervention (m), 
mean±SD
318.2±124.3 288.3±127.7 0.307*
Distance walked during 6MWT after intervention (m), 
mean±SD
324.8±129.4 301.8±123.8 0.434*
Improvement in distance walked during 6MWT after 
intervention (m), median (IQR)
7.3 (−3.7 to 17.1) 16.0 (4.8–25.1) 0.026†
Percentage of improvement after intervention in 6MWT, 
median (IQR)
1.9 (−0.8 to 0.5) 5.7 (1.3–10.7) 0.012†
Speed of walking during 6MWT before intervention (m/s), 
mean±SD
0.88±0.34 0.80±0.35 0.307*
Speed of walking during 6MWT after intervention (m/s), 
mean±SD
0.90±0.36 0.84±0.34 0.443*
Improvement in speed of walking after intervention (m/s), 
median (IQR)
0.02 (−0.01 to 0.05) 0.05 (0.01–0.07) 0.029†
Borg RPE scale before intervention, median (IQR) 11 (8.5–13.0) 11.5 (7.8–14.0) 0.381
Borg RPE scale after intervention, median (IQR) 11 (8.5–13.0) 11 (7.0–13.3) 0.962
Borg RPE scale change, median (IQR) 0 (0,2) 0 (−2,1) 0.065
Numerical ration scale for discomfort due to intervention, 
median (IQR)
1 (0–2.5) 4 (3–6) <0.001
*'t- test.
†Mann- Whitney U- test.
6MWT, Six- Minute Walk Test; RIPC, remote ischaemic preconditioning; RPE, rate of perceived exertion.
Table 4 Number of patients with MCID in 6MWT after 
interventions
MCID criteria
Sham 
intervention 
(n=37)
RIPC 
intervention 
(n=38) P value*
Improvement of 
7% in the distance 
walked after 
intervention18
6 (16.2%) 15 (39.5%) 0.025
Improvement of 
9.1 m in distance 
walked after 
intervention19
15 (40.5%) 26 (68.4%) 0.015
Improvement 
of 21.6 m in the 
distance walked 
after intervention19
5 (13.5%) 13 (34.2) 0.036
*Pearson χ2 test.
MCID, minimal clinically important difference; 6MWT, Six- Minute 
Walk Test; RIPC, remote ischaemic preconditioning.
Table 5 Adverse events of both sham intervention and 
RIPC intervention groups, providing number (per cent)
Adverse events
Sham intervention 
(n=37)
RIPC intervention 
(n=38)
Tingling 5 (13.5%) 17 (44.7%)
Redness of skin 13 (35.1%) 16 (42.1%)
Pins and needles 2 (5.4%) 10 (26.3%)
Skin marking 2 (5.4%) 8 (21.1%)
Pain 0 3 (7.9%)
Uncomfortable 1 (2.7%) 3 (7.9%)
Numbness 1 (2.7%) 2 (5.3%)
Tightness 2 (5.4%) 1 (2.6%)
Swelling ingers 
or hand
4 (10.8%) 0
Others
  
  
1- Unbalanced 1- Slightly dizzy
2- Cold ingers 1- Hot in forearm 
and hand
1- Light headed   
None 19 (51.4%) 3 (7.9%)
RIPC, remote ischaemic preconditioning.
(p=0.012). The NRS for discomfort due to intervention 
was greater in the RIPC group compared with the sham 
group (p<0.001). The number of responders as defined 
by MCID in 6MWT is shown in table 4.
The number of responders in the RIPC group was 
significantly greater irrespective of the criteria for MCID 
used.
We did not encounter any serious adverse event and 
none of the patients withdrew from this study because of 
side effect. Adverse events of both sham and RIPC inter-
vention groups are shown in table 5.
The common adverse events in RIPC intervention 
group were tingling (44.7%), redness of skin (42.1%)), 
pins and needles (26.3%), and skin marking (21.1%).
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DISCUSSION
This trial was the first clinical study of RIPC in patients 
with MS. Previous clinical studies have focused on patients 
suffering acute coronary events, undergoing cardiac 
surgery or stroke, while non- clinical studies have mainly 
involved performance of sports persons.10 20–22 Such 
studies have demonstrated the safety and tolerability of 
RIPC. A recent systematic review demonstrated that RIPC 
improved time- trial performance in 67% of athletes,10 
another demonstrated improved maximal knee extensor 
strength after a single session of RIPC in chronic stroke.22
Cammara- Lemeroy and colleagues recently hypoth-
esised potential mechanistic benefits of RIPC in MS.23 
There are two main ways RIPC could induce neuropro-
tective changes: (1) via ischaemic/hypoxic mechanisms 
and (2) protection against inflammatory demyelination/
neurodegeneration. Unpublished data from a thesis 
evaluating the effect of RIPC on forearm blood flow and 
muscle oxygen use in individuals with MS during hand-
grip exercise did not indicate an effect of RIPC on exer-
cise hyperaemia24; however, the sample size was very small, 
with only four healthy controls and four patients with MS.
Our intervention group included 18.4% of secondary 
progressive multiple sclerosis (SPMS) and 10.5% of 
primary progressive multiple sclerosis (PPMS). The sham 
group, on the other hand, included lower proportions 
of both SPMS (2.7%) and PPMS (5.4%), reflecting in a 
greater level of disease severity in the intervention group 
(median Extended Disability Status Scale (EDSS) score 
of 5.0 in the RIPC group and median EDSS of 3.5 in the 
sham group). The beneficial effects of RIPC on gait were 
thus demonstrated despite greater disease severity in the 
intervention group.
Seventy- seven out of 237 approached patients (32.5%) 
were recruited for the study, a similar recruitment rate 
to studies randomising exercise therapy for people with 
MS.25
A recent systematic review and meta- analysis of the 
effect of functional electrical stimulation for foot drop 
on gait speed in MS found a statistically significant initial 
and ongoing orthotic effect with increase in gait speed 
of 0.05 and 0.08 m/s, respectively on short- walk tests (eg, 
10 m and 25 ft) but no initial or ongoing effects on gait 
speed in long- walk tests (eg, 2 or 6 min walk).26 Our study 
found similar improvements in gait speed after RIPC 
(0.05 m/s) even after walking longer distances (6MWT). 
A recent study on the long- term efficacy of fampridine 
in gait- impaired patients with MS showed walking endur-
ance using 6MWT improved by 11.9%, much greater than 
the 5.7% increment we see with single RIPC; however, 
we do not yet know whether longer term RIPC would 
result in even greater walking distances. da Mota and 
Marocolo highlighted that 50% of studies investigating 
the effect of IPC on exercise tolerance did not include 
an effective placebo group.27 We used a sham interven-
tion and demonstrated that it is feasible to conduct a 
double- blind randomised control trial for RIPC. While 
no participants experienced any serious adverse events, 
milder side effects were more common, such as transient 
redness and sensory disturbances of the arm. Both inter-
ventions were tolerated; however, patients in the RIPC 
group graded intervention discomfort as higher (median 
of 4 on a Likert scale of 0–10) than the participants in 
the sham group (median of 1 on a Likert scale of 0–10). 
This was comparable to the average discomfort scores of 
RIPC (4/10) reported by Lalonde and Curnier in healthy 
individuals.28 Based on these results, we do not think a 
crossover design is appropriate for a clinical trial of RIPC.
Walking distances improved in the sham group (7.3 m, 
p=0.026). This may have been due to familiarisation with 
the 6MWT walkway. A longer study with multiple 6MWT 
may help to answer this question. The Borg RPE scale 
before and after intervention or sham was not signifi-
cantly different; however, the sample size calculation in 
this study was based on 6MWT and may not have been 
powered to detect more subtle changes in this outcome.
Limitations
Our review of literature showed several small single- 
centre RIPC trials with positive outcomes in different 
health conditions, only for no beneficial outcome to be 
identified in subsequent definitive trials.20 We adminis-
tered only a single cycle of RIPC in a clinical research 
setting and studied its immediate effect on 6MWT. As we 
did not study effects of multiple regular RIPC and longer 
term effects, we do not know whether RIPC produces any 
sustained benefit in people with MS. This study involved 
a single quaternary referral centre and recruited only 
patients who could walk for 6 min, limiting the generalis-
ability of the results. We are in the process of performing 
a community- based study evaluating the effects of 6 weeks 
of daily RIPC on activity and gait.
CONCLUSION
This is the first clinical trial of RIPC on gait in patients 
with MS. A significant number of patients achieved a 
beneficial MCID in the primary outcome of walking 
distance. RIPC is a safe and well- tolerated intervention.
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